Protara Therapeutics (TARA) Operating Leases (2019 - 2026)

Protara Therapeutics (TARA) has reported Operating Leases for 8 consecutive years, with $1.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Leases fell 41.35% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $1.8 million (down 41.35% YoY), while the FY2025 annual figure was $2.1 million, down 36.98% from the prior year.
• Operating Leases declined to $1.8 million in Q1 2026 per TARA's latest filing, from $2.1 million in the prior quarter.
• Across five years, Operating Leases topped out at $6.2 million in Q1 2022 and bottomed at $1.8 million in Q1 2026.
• Historically, Operating Leases has averaged $4.4 million across 5 years, with a median of $4.5 million in 2023.
• Annual changes were most pronounced in 2022 — Operating Leases surged 477.86% — and 2026, when it sank 41.35%.
• Protara Therapeutics' Operating Leases stood at $5.5 million in 2022, then dropped by 17.98% to $4.5 million in 2023, then declined by 25.09% to $3.4 million in 2024, then plunged by 36.98% to $2.1 million in 2025, then dropped by 15.3% to $1.8 million in 2026.
• Business Quant data shows TARA's Operating Leases at $1.8 million in Q1 2026, $2.1 million in Q4 2025, and $3.7 million in Q3 2025.